EditorialKommentar
Savings Associated With “Skinny Label” Biosimilars
JAMA Internal Medicine · 2023
DOI: 10.1001/jamainternmed.2022.5418 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Eric Ward und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Biosimilar PharmaceuticalsHumansDrug ApprovalCost SavingsIncome
Substanzen
Biosimilar Pharmaceuticals
Autor:innen und Institutionen
- Department of Medicine, University of California, San Francisco.
- Editorial Fellow, JAMA Internal Medicine.
- Editor at Large and Online Editor, JAMA Internal Medicine.
Zitieren
APA
Ward, E., & Steinbrook, R. (2023). Savings Associated With “Skinny Label” Biosimilars. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.5418
Vancouver
Ward E, Steinbrook R. Savings Associated With “Skinny Label” Biosimilars. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2022.5418
BibTeX
@article{Ward2023,
author = {Ward, Eric and Steinbrook, Robert},
title = {Savings Associated With “Skinny Label” Biosimilars},
journal = {JAMA Internal Medicine},
year = {2023},
doi = {10.1001/jamainternmed.2022.5418}
}
EUVIMED